MedTrace Logo

Cofrogliptin Once Every 2 Weeks as Add-on Therapy to Metformin and Dapagliflozin Versus Daily Linagliptin in Patients With Type 2 Diabetes.

NCT07019012 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 170

Last updated 2025-06-13

No results posted yet for this study

Summary

This study is designed to evaluate the change in glycated hemoglobin (HbA1c) levels from baseline to 24 weeks after the combination therapy of cofrogliptin, metformin and SGLT2i (dapagliflozin) in type 2 diabetes mellitus (T2DM) patients with poor control of glucose level by metformin and SGLT2i combination therapy.

Conditions

  • T2DM

Interventions

DRUG

SGLT2i+Metformin+Cofrogliptin

The combination of SGLT2i+Metformin+Cofrogliptin

DRUG

SGLT2i+Metformin+Linagliptin

The combination of SGLT2i+Metformin+Linagliptin

Sponsors & Collaborators

  • Renmin Hospital of Wuhan University

    collaborator OTHER

  • Wuhan Central Hospital

    collaborator OTHER

  • Taihe Hospital

    collaborator OTHER

  • Xiangyang No.1 People's Hospital

    collaborator OTHER

  • The First Affiliated Hospital of Nanchang University

    collaborator OTHER

  • Huazhong University of Science and Technology

    lead OTHER

Principal Investigators

  • XueFeng Yu, Doctor · Tongji Hosptial Affiliated to Tongji Medical College of Huazhong University fo Science and Technology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-30
Primary Completion
2026-10-30
Completion
2026-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07019012 on ClinicalTrials.gov